Brief: Avalon GloboCare Says SenlangBio Has Initiated First-In-Human Clinical Trial In Recurrent Brain Cancer

Change Agents

01/07/2021 14:23

July 1 (Reuters) - Avalon Globocare Corp  AVCO.O :
    * AVALON GLOBOCARE ANNOUNCES ITS PLANNED ACQUISITION TARGET,
SENLANGBIO, HAS INITIATED FIRST-IN-HUMAN CLINICAL TRIAL IN
RECURRENT BRAIN CANCER
    * AVALON GLOBOCARE CORP - ANTI-EPHA2 CAR-T THERAPY APPEARS
TO BE
WELL-TOLERATED THUS FAR, BASED ON INITIAL SAFETY DATA FROM FIRST
PATIENT COHORT

Source text for Eikon:  ID:nGNX5VH2tv 
Further company coverage:  AVCO.O 

 ((Reuters.Briefs@thomsonreuters.com;))